Stockreport

Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC]

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently' Bluebird Bio Bluebird's therapy, Zynteglo, was approved in Eur [Read more]